Loading…
← CockpitCompetitor Analysis › 300981.SZ Zhonghong Pulin Medical Products Co., Ltd. Class AOpen in the cockpit ↗

Zhonghong Pulin Medical Products Co., Ltd. Class A300981.SZCompetitor analysis, valuation and peers

China · CNY·Consumer Discretionary›Apparel/Footwear

Chinese maker of medical and protective apparel products such as surgical gowns and protective clothing.

Momentum strong 77
Mkt cap
$990M
US dollars, full cap
Free float
97%
of shares outstanding
$/day
$70.1M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+1.3 pp
WACC 6.3%
Hurdle
+11 pp
Req g minus delivered
Close · CNYCN¥15.39
1D-2.5%
1W+2.9%
1M-21.0%
3M+4.8%
6M+5.1%
YTD+22.5%
1Y+13.9%
ATR %9.4%
52w lowhigh40.6% off high

What Zhonghong Pulin Medical Products does

Chinese maker of medical and protective apparel products such as surgical gowns and protective clothing.

Products and services

  • Surgical/protective gowns
  • Medical disposable apparel

Customers

  • Hospitals
  • PPE distributors

Where it sits in the supply chain

  • Healthcare/apparel
  • Medical protective products
  • Surgical gowns/PPE

What could go right

  • Healthcare PPE demand

What could go wrong

  • PPE price competition post-pandemic normalization

Moat: none. Competitive PPE/protective-apparel manufacturing without strong differentiation.

Headquarters: China · Employees: 3,884

Zhonghong Pulin Medical Products at a glance

Size Zhonghong Pulin Medical Products (300981.SZ) is a China Consumer Discretionary company (Apparel/Footwear) with a market value of $990M, the 2318th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥15.39 on 6 Nov 2026.

Performance Over six months the shares gained 5.1%, against -14.1% for the median peer and -16.4% for the China market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue grew 11.0% over the last twelve months (peer median +5.5%); the operating margin is 8.8% (peer median 5.2%).

Valuation It trades at 1.9× enterprise value to sales against a peer median of 1.7× (10th most expensive of 21).

Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is -13%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.3 points above its cost of capital (6.3% WACC).

Relative performance

10015011 May 202611 Aug 20266 Nov 2026300981.SZ 103Peer median 87
Six months, rebased to 100: Zhonghong Pulin Medical Products against the median of its 20 peers (local-currency closes).

Zhonghong Pulin Medical Products financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.75BCN¥2.37BCN¥2.45BCN¥2.10BCN¥1.56B
Revenue growth—-4%+17%+34%—
Gross profitCN¥748MCN¥197MCN¥269MCN¥212MCN¥131M
EBITDAn/aCN¥104MCN¥182MCN¥26.2M-CN¥1.90M
Net incomeCN¥148M-CN¥112M-CN¥87.1M-CN¥131MCN¥66.9M
Free cash flowCN¥530M-CN¥89.5MCN¥162MCN¥37.6M-CN¥5.56M
Capital expenditureCN¥104MCN¥191MCN¥107MCN¥103MCN¥208M
Total debtCN¥1.79BCN¥1.57BCN¥1.12BCN¥663MCN¥194M

Quarterly statements and history in the cockpit →

Zhonghong Pulin Medical Products competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%601566603196603587603608600400456A6017186890000712002029BATAINDIAGOOS603877002612DOCS3000053591SFER0022541368300981.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Zhonghong Pulin Medical Products is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%+20%5×10×601566603196603587603608600400456A6017186890000712002029BATAINDIAGOOS603877DOCS30000535910022541368300981.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhonghong Pulin Medical Products is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%601566603196603587603608600400002029BATAINDIAGOOS6038770026123591SFER0022541368300981.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Zhonghong Pulin Medical Products is the large dot.

Zhonghong Pulin Medical Products competitors and peer comparison

How Zhonghong Pulin Medical Products compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhonghong Pulin Medical Products against its 20 peers (data as of 6 Nov 2026)
Measure300981.SZPeer medianRank in peer set
1-month return-21.0%-3.5%lowest of 21
6-month return+5.1%-14.1%6th highest of 21
Distance from 52-week high-40.6%-39.8%10th lowest of 21
Revenue growth (TTM)+11.0%+5.5%6th highest of 21
Operating margin8.8%5.2%8th highest of 21
EV / Sales1.9×1.7×10th most expensive of 21
Growth the price implies (Req g, 7 yrs)-1.7%6.6%6th least demanding of 17
Growth delivered (Del g)-13.1%+2.1%lowest of 16
Hurdle (Req g minus delivered)+11.5 pp+2.0 pp7th most demanding of 16
ROIC minus cost of capital+1.3 pp-2.0 pp9th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Zhonghong Pulin Medical Products 300981.SZChina$990M+5%+11%9%1.9×-1.7%-13.1%
JOEONE 601566.SSChina$975M+4%+1%6%1.7×-2.9%+2.1%
Shanghai Puyuan Chemical Materials 603196.SSChina$964M-46%+78%12%4.3×16.2%-0.2%
Dazzle Fashion 603587.SSChina$1.03B+10%+7%16%1.9×-9.2%-3.5%
Topscore Fashion 603608.SSChina$1.05B+28%+9%4%5.9×51.6%-9.4%
Jiangsu Hongdou Industrial 600400.SSChina$1.06B+11%+22%-9%3.0×13.7%-1.3%
Human Made 456A.TJapan$1.10B+39%+27%30%9.6×7.7%n/a
Jihua 601718.SSChina$1.10B-43%-22%-10%0.8×n/an/a
Lai Yih Footwear 6890.TWTaiwan$1.11B-7%-11%8%1.0×n/an/a
Guangdong Golden Dragon Development 000712.SZChina$1.12B-20%-3%-20%17.5×n/an/a
Fujian Septwolves Industry 002029.SZChina$873M-20%+1%-3%1.4×4.5%-2.0%
Bata India BATAINDIA.NSIndia$868M-12%+5%9%2.6×28.9%+15.5%
Canada Goose GOOS.TOCanada$850M-23%+12%10%1.2×5.5%+11.0%
Ningbo Peacebird Fashion 603877.SSChina$839M-15%-2%4%0.8×-13.1%-7.5%
Lancy 002612.SZChina$1.19B+11%+9%10%1.6×-1.2%+15.9%
Dr. Martens DOCS.LUnited Kingdom$824M+3%-3%10%1.1×-3.7%-0.2%
Toread 300005.SZChina$1.21B-45%+22%-1%4.6×n/an/a
Wacoal 3591.TJapan$1.21B-21%+2%-1%1.1×35.7%+2.4%
Salvatore Ferragamo SFER.MIItaly$1.22B-19%-2%3%1.6×22.5%+2.2%
Tayho Advanced Materials 002254.SZChina$1.26B-13%+6%-2%3.0×10.1%+8.1%
Xtep International 1368.HKHong Kong$1.27B-16%+10%10%0.5×-10.3%+10.8%

Questions

Which companies are Zhonghong Pulin Medical Products's closest peers?
The cockpit's peer set: JOEONE (601566.SS), Shanghai Puyuan Chemical Materials (603196.SS), Dazzle Fashion (603587.SS), Topscore Fashion (603608.SS), Jiangsu Hongdou Industrial (600400.SS), Human Made (456A.T), Jihua (601718.SS), Lai Yih Footwear (6890.TW).
Is Zhonghong Pulin Medical Products expensive compared with its peers?
On ev / sales it trades at 1.9× against a peer median of 1.7×, 10th most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is -13%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Zhonghong Pulin Medical Products stock performed?
Over six months to 6 Nov 2026 the shares returned +5.1% against -14.1% for the median peer; over one year +13.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.